CureVac GmbH, a spin-out from the
The investors who contributed to the new round include two
venture capital funds DH Capital GmbH & Co. KG and OH Beteiligungen GmbH
& Co. KG. CureVac received €2.7 million from Leonhardo Venture in a first
round financing in 2003.
“We will use the new investment for clinical trails,” said
Dr. Ingmar Hoerr, co-founder and CEO of CureVac, in an interview. “It could
last us for about 4 years then we might be opening a third financing round or
it could be an IPO. We will get the phase one data at the end of 2007 and then
we start phase two study. We will get the studies in 2009 or 2010.”
CureVac is trying to develop vaccines that are based on its
RNActive technology which is aimed specifically at treating and preventing
tumours. The RNA technology is a hot new
market sector, aimed at turning off or regulating specific genes. The aim is to
treat various human diseases.
CureVac GmbH, a spin-out of
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
